Our aim was to assess the ability of convection-enhanced drug delivery (CED), a novel approach of direct delivery of drugs into brain tissue and brain tumors, to treat brain tumors using salirasib (farsnesyl thiosalicylic acid). CED was achieved by continuous infusion of drugs via intracranial catheters, thus enabling convective distribution of high drug concentrations over large volumes while avoiding systemic toxicity. Several phase II/III CED-based trials are currently in progress but have yet to overcome two major pitfalls of this methodology (the difficulty in attaining efficient CED and the significant nonspecific neurotoxicity caused by high drug doses in the brain). In this study, we addressed both issues by employing our previously described novel CED imaging and increased efficiency methodologies to exclusively target the activated form of the Ras oncogene in a 9L gliosarcoma rat model. The drug we used was salirasib, a highly specific Ras inhibitor shown to exert its suppressive effects on growth and migration of proliferating tumor cells in in vitro and in vivo models, including human glioblastoma, without affecting normal tissues. The results show a significant decrease in tumor growth rate in salirasibtreated rats relative to vehicle-treated rats as well as a significant correlation between CED efficacy and tumor growth rate with no observed toxicity despite drug concentrations an order of magnitude higher than previously detected in the brain. The results show that CED of salirasib is efficient and nontoxic for the treatment of glioblastoma in a rat model, thus suggesting that it may be considered for clinical application.
Introduction
Fluid convection (bulk flow), which occurs in the brain interstitial fluid under normal conditions (1) , in cases of vasogenic edema (2) , and after infusion of solutions directly into the brain parenchyma (3) , is a promising technique for the distribution of solutions into brain tissue. The fluid convection established by maintenance of a pressure gradient during interstitial infusion has been shown to greatly enhance the distribution of various molecules in the brain (4, 5) . Those studies showed the ability of fluid convection to obtain in situ drug concentrations several orders of magnitude greater than those achieved by systemic administration over large volumes of the brain at various time intervals. The concentration profile obtained with convectionenhanced drug delivery (CED) is relatively flat up to the flow front, providing control over undesired toxicity (6) .
Application of CED to brain pathology is an emerging field. Most of the studies carried out thus far have focused on the treatment of brain tumors. Our group recently conducted a phase I/II clinical trial in which 15 patients with recurrent glioblastoma multiforme received a total of 20 cycles of intratumoral CED of Taxol with a significant antitumor response rate of 73% (7) . In a phase II clinical trial, in which patients were treated by CED of Tf-CRM107 (a conjugate protein of diphtheria toxin with a point mutation linked by a thioester bond to human transferrin), the response rate was 35% (8) . Clinical trials have also been conducted with other drugs, such as TP-38 (9) and interleukin-4 (38-37)-PE38KDEL (10) , which provided evidence of some clinical activity, and with interleukin-13-PE38QQR (11) , which yielded no definite conclusions with regard to efficacy.
In a recent study aimed at integrating drugs into the CED model, we showed that the readily available magnetic resonance imaging (MRI) contrast agent Gd-DTPA could be used as a surrogate marker for immediate assessment of convection efficiency and infusate distribution simply by being mixed with the infusate before infusion (12) . The cytotoxic response of brain tissue to therapeutic agents infused via CED could be assessed at an early stage by means of subsequent T 2 -weighted and diffusion-weighted MRI. Our data suggested, moreover, that drug distribution can be significantly improved by increasing the infusate viscosity where optimal infusate distribution was achieved with 10% sucrose (12) .
At least some nonspecific neurotoxicity was observed in all the drug models tested. This ongoing problem led us to search for novel drugs that show potential antitumor activity with minimal nonspecific toxicity. A suitable candidate for this purpose might be the Ras inhibitor, farsnesyl thiosalicylic acid (salirasib). Ras proteins comprise a family of small GTPases that act as key regulators of cell signaling pathways governing cell proliferation, differentiation (13), migration (14 -16) , survival, and death (17) . On mitogenic stimulation, these proteins switch from the nonactivated, GDP-bound form to the activated, GTPbound form, and their activity depends on their proper membrane anchorage (18) . Accordingly, salirasib was designed to mimic the farnesyl cysteine moiety of the carboxyl terminus of Ras shown to be crucial for such anchorage. By competing with Ras on membrane anchorage sites, salirasib causes dislodgement and rapid degradation of Ras (19) .
Salirasib has been shown to be effective against human glioma in vitro (16, 20, 21) . Inoculation of human gliomas in animal models is usually done in nude mice, which are too small for convection experiments. Therefore, in the present study, we treated 9L-tumor-bearing rats with a salirasibbased infusate, which we have prepared for CED use by adding Gd-DTPA for real-time imaging of the extent of CED and 10% sucrose to increase viscosity. A control group was treated with a similar infusate without the drug. We found that, relative to the control, a single dose of salirasib caused a marked decrease in tumor growth rate with no apparent toxicity. In addition, a clear and significant correlation was found between tumor growth rate and convection efficiency in the salirasib-treated group only.
These promising results, showing the induction of significant antitumor effects without the nonspecific neurotoxicity seen with most chemotherapeutic agents, suggest that salirasib can be considered as a potential therapy for glioblastoma.
Materials and Methods
Cell Culture Procedures 9L gliosarcoma cells were maintained at 37jC and 5% CO 2 in DMEM enriched with 10% FCS and penicillin/streptomycin 1% and were subcultured twice a week. Cells were plated at a density of 5,000 per well in 24-well plates for direct cell counts or at 1 Â 10 6 per 10 cm plate for biochemical and immunoblotting assays. The cells were incubated for 24 h, treated with the indicated concentration of salirasib or with the vehicle (0.1% DMSO; control) for the times specified in each experiment, and then subjected to the various assays as described below. For 9L implantation, a pellet of 1 Â 10 8 cells suspended in 2 mL PBS was prepared.
Salirasib Preparation For in vitro experiments, salirasib and the control vehicle (0.1% DMSO) were prepared in DMEM at different concentrations, and each mixture was placed in the cell culture plates, so that the final concentrations of salirasib were 0, 6.25, 12.5, 25, 50, or 100 Amol/L, whereas the DMSO concentration was adjusted to 0.1%. Salirasib, a gift from Concordia Pharmaceuticals, was prepared as described previously (22) .
For in vivo experiments, salirasib was dissolved in ethanol and the solution was alkalinized by the addition of 1 N NaOH and then diluted with PBS to obtain a solution of 3.0 mg/mL salirasib (pH 8.0; 1% ethanol). This solution was diluted to create a final concentration of 50 Amol/L salirasib in PBS containing 10% sucrose based on our previous experiments (12) . For preparation of the control vehicle, we used ethanolic PBS without salirasib.
Cell Growth Assay 9L cells were treated with salirasib (6.25, 12.5, 25, 50, or 100 Amol/L) or DMSO (0.1%) for 5 days. The effect of salirasib on cell growth was determined by direct counting of cells collected from each well. To calculate the average percentage of viable cells (mean F SD, n = 4), we divided the number of cells counted for each salirasib concentration by the number of cells in the control group. The experiment was down in quadruplicate.
GTPase Pull-down and Western Blotting Assays 9L cells were treated with salirasib (25 or 50 Amol/L) or DMSO (0.1%) for 24 h. The cells were then stimulated with epidermal growth factor (100 ng/mL; 5 min) and lysed. Lysates containing 1 mg protein were used to determine the Ras-GTP content by the glutathione S-transferase-RBD (Ras-binding domain of Raf) pull-down assay as described elsewhere (23) . Total lysates and pull-down supernatants were subjected to SDS-PAGE and then immunoblotted with the following antibodies: anti-pan-Ras (1:2,500), antiphospho-extracellular signal-regulated kinase (ERK; Thr 183 and Tyr 185 ; 1:10,000), anti-ERK2 (1:1,000), and anti-h-tubulin (1:500). The immunoblots were exposed either to 1:2,500 peroxidase goat anti-mouse IgG or to 1:2,500 peroxidase goat anti-rabbit IgG, and protein bands were visualized by enhanced chemiluminescence and quantified by densitometry using EZQuant-Gel 2.1 software (EZQuant). Mouse anti-pan-Ras antibody (Ab-3) was from Calbiochem; mouse anti-phospho-ERK antibody and mouse anti-h-tubulin antibody were from Sigma-Aldrich; rabbit anti-ERK antibody was from Santa Cruz Biotechnology.
In vivo Experimental Design A treatment solution containing salirasib and a control solution (without salirasib) were mixed with 10% sucrose (for increased efficacy) and with Gd-DTPA (1:70; for realtime imaging) and infused into the striatum of 9L gliosarcoma-bearing Fisher rats (males; 250-300 g) for the efficacy studies and into the striatum of normal Fisher rat brains for the toxicity studies.
For the efficacy studies, the extent of convection and the tumor volume at baseline were assessed by T 1 -and T 2 -weighted MRI acquired immediately after treatment. T 2 -weighted and contrast-enhanced T 1 -weighted MRI were acquired periodically thereafter to monitor tumor growth rate. The growth rate of treated rats relative to that of control rats as well as the correlation between extent of CED and tumor growth rate was studied as functions of time after treatment.
For the toxicity studies, the extent of convection was assessed by T 1 -weighted MRI acquired immediately after treatment. Procedure-related toxicity (such as hydrocephalus caused by infusion into the ventricles) was assessed by T 2 -weighted MRI acquired immediately after the treatment. Early and late tissue toxicity were assessed by T 2 -weighted and diffusion-weighted images acquired 24 h and 2 weeks post-treatment (12) . In addition, the rats' weight was monitored throughout the 2-week follow-up period.
Tumor Implantation Male Fisher rats (250-300 g) were deeply anesthetized by i.m. injections of 600 AL of 22.5 mg/mL ketamine and 0.3% xylasine given twice in 15 min intervals. The striata of the rats were then inoculated with tumors as follows: the bregma was identified through a midline scalp incision, and a 1 mm burr hole was drilled in the right region of the skull, 3 mm anterior and 2 mm lateral to the bregma. A 33-gauge needle attached to a 1,000 AL syringe (Gastight; Hamilton) containing the 9L pellet was placed stereotactically in the striatum at a depth of 5.5 mm. Cells were infused with a syringe pump (Bee Hive; BASi) at a rate of 2 AL/min for 5 min, so that the final number of implanted cells was 5 Â 10 5 . The burr hole was then sealed with bone wax to prevent the tumor from growing out of the skull.
CED Procedure
In the 9L tumor-bearing rats, the burr hole that was drilled for cell implantation was reopened after 4 days and then used for CED treatment. In the rats treated for toxicity (normal rat brains), new burr holes were drilled as described above. Before infusion, Gd-DTPA was added to the salirasib or control solution to a concentration of 1:70. Salirasib or control solution was infused into the tumors for the efficacy studies or the striatum for the toxicity studies of deeply anesthetized rats for 40 min at a rate of 1 AL/min using the syringe pump described above. Both control and salirasib-treated rats were scanned immediately after treatment.
MRI Monitoring
The immediate formation and extent of CED as well as tumor follow-up were assessed with a General Electric 0.5 T interventional MRI machine [Signa SP/i (special proceeding/interventional)] equipped with the LX operating system and at a field-gradient intensity of up to 1 gauss/ cm. The early and late toxicity, using diffusion-weighted MRI, were assessed with a General Electric 3.0 T MR system equipped with the HD 12x operating system and at a fieldgradient intensity of up to 4 gauss/cm. Specially designed animal volume coils, 5 cm in diameter, were used for data acquisition.
T 2 -weighted fast spin echo MRI were acquired with a 256 Â 128 matrix, 12 Â 9 cm 2 field of view, repetition time of 3,000 ms, echo time of 90 ms, and 3 mm slices with no gap. T 1 -weighted images were acquired with a 256 Â 128 matrix, 12 Â 9 cm 2 field of view, repetition time = 400 ms, echo time = 12 ms, and 3 mm slices, no gap. Line-scan diffusion-weighted MRI were acquired with 256 Â 128 matrix, 12 Â 9 cm 2 field of view, repetition time = 5,440 ms, echo time = 142 ms, and 2 mm slices. Due to the limitation of the relatively thick (3 mm) slices on the 0.5 T system, each sequence was scanned twice, where the second time was acquired with a shift of 1.5 mm relative to the first, to enable maximum sensitivity to changes.
Calculation of Extent of CED The gadolinium enhancement obtained from T 1 -weighted MRI reflects the infusate distribution in the rat brain (12) . Thus, the volume (in cm 3 ) of infusate distribution was calculated from the T 1 -weighted MRI acquired immediately after CED treatment. Regions of interest were defined over the entire enhancing region in each slice (excluding the ventricles). Number of pixels in the regions of interest were counted and then multiplied by the volume of a single pixel as described earlier (12) .
Calculation of Tumor Volume
The initial tumor volume (in cm 3 ) was calculated from T 2 -weighted MRI, whereas the extent of CED was calculated from the contrast-enhanced T 1 -weighted MRI at the same session for each rat. For the follow-up, rats were first injected (i.p) with 0.1 mL of 1 mmol/L Gd-DTPA then scanned. The volume of the tumor in these follow-ups was calculated from contrast-enhanced T 1 -and T 2 -weighted MRI. Regions of interest were defined over the entire enhancing region in each slice (excluding the ventricles). Numbers of pixels in the regions of interest were counted and then multiplied by the volume of a single pixel.
Calculation of Tumor Growth Rate
The tumor growth rate for each rat was calculated as the ratio between the tumor volume measured in a certain follow-up scan and the tumor volume measured in the first follow-up scan. The ratio was calculated for each followup scan. Average tumor growth ratios (mean F SE) are presented for the salirasib (n = 13) and the control (n = 19) groups.
Correlation between CED Efficacy and Tumor Growth Rate
The correlation between CED efficacy and tumor growth rate was calculated by plotting the CED volume versus the growth rate for each rat. Correlations were calculated separately for growth rates between the second and first follow-up scans, the third and second follow-up scans, and the third and first follow-up scans.
Results

Salirasib Induces Growth Inhibition and Disruption of Ras Signaling in 9L Cells
Salirasib (farnesyl thiosalicylic acid) was designed as a small-molecule Ras inhibitor (22) . With the aim of integrating salirasib into the CED model, we first examined its effect on the rat 9L gliosarcoma cell line as a brain tumor model. We did this by employing a simple cell growth assay in which 9L cells were treated with salirasib (6.25, 12.5, 25, 50, or 100 Amol/L) or, as a control, with DMSO (0.1%). Five days later, cells were collected and counted. Figure 1A previously to be efficient in terms of growth inhibition in various human cancer cell lines (16, 24 -27) . Under the conditions employed here, cell death (indicated by Hoechst staining), both in the absence and in the presence of Salirasib, was lower than 10% (data not shown).
In addition, salirasib caused a dose-dependent decrease in the epidermal growth factor-stimulated increase in active, GTP-bound Ras as well as a decrease in total Ras (Fig. 1C and D, left) . Salirasib (50 Amol/L) also caused a decrease in epidermal growth factor-stimulated Ras signaling to the Raf/MEK/ERK cascade as indicated by the observed decrease in phospho-ERK (Fig. 1C and D, right) . These findings showed that salirasib acts as an effective Ras inhibitor in rat 9L gliosarcoma cells and therefore has an antiproliferative effect on these cells.
Extent of CED The extent of convection was reflected by the T 1 -weighted MRI acquired immediately after CED treatment with infusates mixed with Gd-DTPA (12) . Poor convection was characterized by significant backflow along the catheter and into the ventricles depicted in the images as significant enhancement in the ventricles and little or no enhancement in the striatum (Fig. 2B) . Efficient convection was reflected by significant spread into the striatum with minimal backflow into the ventricles (Fig. 2A) . In some cases, owing to the characteristically dense tissue texture of massive 9L tumors, if a tumor had grown enough to form a mass at the time of CED treatment (shown in Fig. 2D ), we found evidence of convection around the tumor but little or no penetration into the tumor itself (Fig. 2C) .
Effect of Salirasib on Normal Rat BrainöToxicity Study Twelve naive rats were treated by CED of salirasib or the solvent. One of the rats died due to the surgical procedure. There were no other mortalities. The volume of distribution, as calculated from the immediate T 1 -weighted MRI, was similar for the two groups: salirasib 60.3 F 10.5 mm 3 (n = 5) and control 72.0 F 19.1 mm 3 (n = 6); P < 0.62 (two-tailed Welch-corrected t test).
As shown in Fig. 3 , no toxicity was observed in the MRI acquired for either the control or the salirasib-treated group compared with rats treated with carboplatin, which caused severe tissue damage (Fig. 3) . During the first MRI followup, acquired 24 h post-treatment, 1 control rat showed mild edema in the striatum, which was resolved by the time of second follow-up, 2 weeks later. Two control rats and two salirasib-treated rats showed minor tissue damage at the needle entrance point. These abnormalities were resolved as well by the time of the second follow-up. There were no differences in weight gain between the salirasib-treated group and the control group; 9.6 F 1.4% and 10.5 F 3.9% weight gain over the 2-week follow-up for salirasib or control rats respectively (P < 0.84, two-tailed Welch-corrected t test).
Correlation between CED Efficacy and Tumor Growth Rate
This experiment was done in three sessions. In each session, rats in the treated group (n = 10-12) were treated by CED of salirasib and rats in the control group (n = 10-12) were treated with the solvent. Both groups were monitored by MRI immediately after the treatment and periodically thereafter. CED volumes were calculated from the immediate T 1 -weighted MRI, and tumor volumes were calculated from the T 2 -weighted and contrast-enhanced T 1 -weighted MRI. The results are presented in Table 1 .
The correlation between tumor growth rate (calculated from the first follow-up) and CED volume was significant in two of the three sessions (P < 0.05; Table 1 ). Moreover, the correlation coefficient of the relationship between tumor growth rate and CED volume, r 2 , was high in all three groups (Table 1 ). This suggests that more efficient CED is correlated with increased treatment effects. The correlation coefficient was highest for the group with the smallest initial tumor volume and lowest for the group with the largest initial tumor volume, suggesting that the treatment was more efficient for smaller tumors. In addition, the correlation between CED volume and tumor growth rate decreased with time (Fig. 4) . For example, in the group with the smallest initial tumor volume, the correlation coefficient was high when tumor growth rate was measured between the second and the first follow-ups (r 2 = 0.989), lower when tumor growth rate was measured between the third and the first follow-ups (r 2 = 0.64) and flat when it was measured between the third and the second follow-ups (r 2 = 0.02). These results suggest that the treatment affected tumor growth rate only up to the second follow-up presumably due to the single-dose treatment.
Effect of CED of Salirasib onTumor Growth Rate Altogether, 30 9L tumor-bearing rats were treated with CED of salirasib and 32 9L tumor-bearing rats were treated with CED of the solvent (controls). Tumor volumes as a function of time were calculated from the follow-up MRI scans acquired up to 2 weeks after treatment. Because initial tumor volumes varied between the groups, tumor growth rates were normalized to the initial tumor volume. tissue. Naive rats were convected either with vehicle control, 50 Amol/L Salirasib, or carboplatin (4 mg/mL), which was used as a positive control for toxicity. Typical T 1 -weighted images depicting drug distribution taken immediately after CED (day 0) and typical T 2 -weighted images and diffusion-weighted images taken on day 1 are shown. Also shown are typical T 2 -weighted images taken 14 d after CED. The T 1 -weighted images on day 0 show efficient CED in the various treatments. The T 2 -weighted and diffusionweighted images on day 1 show lack of early tissue toxicity in control and salirasib-treated rats compared with the carboplatin treated rat, which exhibited tissue damage in the form of edema and hydrocephalus. Late tissue toxicity (T 2 , day 14) was observed only in the carboplatin-treated rat, which exhibited significant tissue necrosis and hydrocephalus.
In the salirasib-treated group, tumor growth was significantly slower for up to 2 weeks after treatment. Average tumor growth rates (normalized in each rat to the initial tumor volume and then averaged over the group of rats) were as follows: at 7 days, 1.15 F 0.14 in salirasib-treated rats compared with 1.85 F 0.22 in control (P < 0.015), and at 10 days, 1.61 F 0.32 in salirasib-treated rats compared with 3.22 F 0.55 in control (P < 0.023; Fig. 5A ). At the last followup, the difference between the groups was not significant (1.87 F 0.44 in salirasib-treated rats compared with 3.94 F 0.75 in control; P < 0.085) probably because of the small number of surviving rats, which was also reflected by lack of difference in overall survival between the two groups. However, we found that in the surviving salirasib-treated rats the convection volumes were significantly higher (2.1 F 0.25-fold) compared with the volumes of the nonsurviving rats (Fig. 5B) . By contrast, in the control group, the convection volume ratio of surviving/nonsurviving rats was 1.3 F 0.69, not significantly different than 1.0 (Fig. 5B) . These results suggest that improved convection of salirasib correlates with increased survival rate.
Discussion
Glioblastomas are highly aggressive tumors for which there is no adequate treatment to date and are therefore associated with poor life expectancies where the median survival at 1 year is about 50% (28) . Among other anomalies of gene expression, these tumors harbor a chronically activated Ras oncogene as a consequence of overexpression of growth factors and their receptors (29) . Various attempts at Ras-directed therapy over the last decade have met with little success, leaving this therapeutic path wide open for novel agents (30) . In this study, we employed the specific Ras inhibitor salirasib, which was originally designed to compete with Ras for its binding sites, thereby causing it to become dislodged from the cell membrane and subsequently undergo rapid degradation (19) . Salirasib was shown previously to be highly potent in cell culture systems (24 -27), in soft-agar assays (31, 32) , and in various in vivo murine models (32 -36) . Promoter and biochemical analyses of glioblastoma cells treated with salirasib have disclosed that two important Ras-controlled transcription factors are down-regulated by the treatment. One is hypoxia-inducible factor-1, whose down-regulation leads to glycolysis shutdown (20) , and the other is E2F1, whose down-regulation is associated with cell cycle arrest (21) . In addition, salirasib, by inhibiting both anchorageindependent cell growth and cell migration, was shown to avert the malignant phenotype of glioblastoma cells (16) . These findings support the candidacy of salirasib as a potential therapy for glioblastoma multiforme. Salirasib is currently undergoing trials in patients with pancreatic cancer and with non-small cell lung cancer. 4 In a study carried out by our group in a mouse model of head trauma (in which the blood-brain barrier is impaired), the highest concentrations of salirasib measured in brain homogenates from treated rats were of the order of 4.5 Amol/L (37). In the present study, the concentration of salirasib that was delivered directly into the tissue was 50 Amol/L, which is the concentration that was shown to effectively inhibit cell growth in vitro (Fig. 1) .
Showing CED efficacy in a rat brain tumor model is hampered by the difficulty in simulating human brain tumor characteristics in means of tissue consistency and tumor infiltration. In humans, CED efficacy has been shown to vary among different drugs, from very high to very low response rates with various toxicity levels. In a previous publication, we have suggested that some of the differences between treatment effects obtained by different drugs may be explained by poor convection extent obtained with low viscosity infusates. Therefore, the main goal of the presented research was to show that salirasib can be efficiently distributed in a brain tumor model using a high-viscosity infusate and that treatment efficacy is increased with increased distribution volumes.
The results of this study show the significant efficacy of salirasib, administered via CED, in inhibiting tumor growth in a rat 9L tumor model. It is important to note that the present results were the outcome of a single CED treatment carried out soon after tumor implantation. In most animal models, it is practically impossible to repeat the CED treatment, because once the tumor becomes massive (detectable on MRI) drug penetration into the tumor becomes progressively more limited. This limitation can probably explain the lack of significant improvement in overall survival of the salirasib-treated rats (data not shown), although significant treatment effects were obtained from the overall tumor growth rates and the correlation with CED efficacy. In spite of the limitation, our results suggest that improvement in CED may allow its use also for large tumors and/or for high cellular density tumors. Indeed, we show that increased salirasib convection volumes correlate positively with survival (Fig. 5B) .
Within each of the three sessions, the correlation between tumor growth rate and convection volume (drug distribution volume) was high, and in two of them, it was significant. This finding suggests that a more efficient CED is correlated with increased treatment effects and highlights the importance of achieving efficient convection of the drug within the tissue. Salirasib is normally dissolved in a low-viscosity solvent consisting of ethanolic PBS. In this study, we increased the viscosity of the solvent by adding 10% sucrose, thus enabling efficient CED, as discussed in our previous work (12) .
The correlation coefficient was highest for the group with the smallest initial tumor volume and lowest for the group with the largest initial tumor volume, suggesting that the treatment was more efficient in smaller tumors. This phenomenon might be explained in terms of the texture of the 9L tumors; once they grow large enough to be imaged by MRI, they can no longer be efficiently penetrated by convection. An example is shown in Fig. 2C and D, where the delivered drug was adequately distributed by convection around the tumor, but no penetration was detectable.
The correlation between tumor growth and CED volume (efficacy) decreased with time after treatment in all three sessions as shown in Fig. 4 . This effect is presumably attributable to the fact that the delivered drug was unable to penetrate to the full depth of the tumor, with resulting occurrence of residual tumor growth. As mentioned before, these tumors do not simulate well clinical tumors; therefore, the main goal of the study was to show significant treatment effect and its dependence on CED efficacy rather than improved overall survival. Figure 5 . Effect of salirasib on tumor growth rate. A, average tumor growth rates (normalized in each rat to the initial tumor volume and then averaged over the group of rats) as a function of time after treatment for salirasib-treated rats and controls. Tumor growth rate was significantly slower in the salirasib-treated rat for up to 2 weeks after treatment. B, ratio between convection (CED) volumes in surviving and nonsurviving rats is shown for control and salirasib-treated rats (mean F SD). The observed 2.1-fold increase in CED volume in the salirasib-treated group was highly significant (P < 0.0017, surviving rats versus nonsurviving rats in this group). In the control group, there was no significant difference (1.3-fold increase; P < 0.128).
In summary, the results of this study show, both in vitro and in vivo, the efficacy of salirasib in the treatment of brain tumors in a glioma rat model. In addition, the present results emphasize the importance of achieving efficient convection to maximize treatment efficacy. Our findings also highlight the importance of delivering drug concentrations high enough to serve as therapeutic doses not achievable by i.v. administration.
A unique characteristic of salirasib is its remarkable specificity for tumor tissue, which makes it an optimal drug for CED. We have observed no toxicity in either our in vitro or our in vivo studies (Figs. 1 and 3) despite the fact that the concentrations used in this work were at least an order of magnitude higher than previously reported salirasib concentrations detected in the brain (37) .
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